Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Zignol

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Tuberculosis (Edinburgh, Scotland)|July 14, 2012
Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projectsEkaterina V Kurbatova, Allison Taylor, Victoria M Gammino, et al.
The Lancet. Infectious Diseases|March 28, 2013
Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for actionWilliam A Wells, Catharina C Boehme, Frank G J Cobelens, et al.
Plos Medicine|January 22, 2020
Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional dataAnna S Dean, Matteo Zignol, Andrea Maurizio Cabibbe, et al.
Plos Medicine|January 24, 2023
The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling studyAllison Portnoy, Rebecca A Clark, Matthew Quaife, et al.
The Lancet. Global Health|March 16, 2023
The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling studyRebecca A Clark, Christinah Mukandavire, Allison Portnoy, et al.
The Lancet. Infectious Diseases|April 17, 2025
The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistanceHatim Sati, Elena Carrara, Alessia Savoldi, et al.
The Lancet. Respiratory Medicine|November 2, 2025
Climate change and tuberculosis: an analytical frameworkMatthew J Saunders, Delia Boccia, Palwasha Y Khan, et al.
Vaccine|February 15, 2022
Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test caseSonali Kochhar, Draurio Barreira, Pauline Beattie, et al.
The Lancet. Microbe|April 4, 2022
The 2021 WHO catalogue of <i>Mycobacterium tuberculosis</i> complex mutations associated with drug resistance: A genotypic analysisTimothy M Walker, Paolo Miotto, Claudio U Köser, et al.
Bulletin of the World Health Organization|November 14, 2023
Target product profiles: tests for tuberculosis treatment monitoring and optimizationAnkur Gupta-Wright, Saskia den Boon, Emily L MacLean, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Tuberculosis (Edinburgh, Scotland)|July 14, 2012
Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projectsEkaterina V Kurbatova, Allison Taylor, Victoria M Gammino, et al.
The Lancet. Infectious Diseases|March 28, 2013
Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for actionWilliam A Wells, Catharina C Boehme, Frank G J Cobelens, et al.
Plos Medicine|January 22, 2020
Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional dataAnna S Dean, Matteo Zignol, Andrea Maurizio Cabibbe, et al.
Plos Medicine|January 24, 2023
The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling studyAllison Portnoy, Rebecca A Clark, Matthew Quaife, et al.
The Lancet. Global Health|March 16, 2023
The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling studyRebecca A Clark, Christinah Mukandavire, Allison Portnoy, et al.
The Lancet. Infectious Diseases|April 17, 2025
The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistanceHatim Sati, Elena Carrara, Alessia Savoldi, et al.
The Lancet. Respiratory Medicine|November 2, 2025
Climate change and tuberculosis: an analytical frameworkMatthew J Saunders, Delia Boccia, Palwasha Y Khan, et al.
Vaccine|February 15, 2022
Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test caseSonali Kochhar, Draurio Barreira, Pauline Beattie, et al.
The Lancet. Microbe|April 4, 2022
The 2021 WHO catalogue of <i>Mycobacterium tuberculosis</i> complex mutations associated with drug resistance: A genotypic analysisTimothy M Walker, Paolo Miotto, Claudio U Köser, et al.
Bulletin of the World Health Organization|November 14, 2023
Target product profiles: tests for tuberculosis treatment monitoring and optimizationAnkur Gupta-Wright, Saskia den Boon, Emily L MacLean, et al.
Pageof 9